Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash & Equivalents (2017 - 2025)

Serina Therapeutics' Cash & Equivalents history spans 9 years, with the latest figure at $8.6 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 168.75% year-over-year to $8.6 million; the TTM value through Sep 2025 reached $8.6 million, up 168.75%, while the annual FY2024 figure was $3.7 million, 51.8% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $8.6 million at Serina Therapeutics, up from $6.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $8.7 million in Q1 2024 and bottomed at $261000.0 in Q2 2023.
  • The 5-year median for Cash & Equivalents is $755500.0 (2021), against an average of $3.0 million.
  • The largest annual shift saw Cash & Equivalents plummeted 62.82% in 2023 before it surged 3007.14% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $600000.0 in 2021, then changed by 0.0% to $600000.0 in 2022, then soared by 1169.83% to $7.6 million in 2023, then crashed by 51.8% to $3.7 million in 2024, then soared by 134.2% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Cash & Equivalents are $8.6 million (Q3 2025), $6.0 million (Q2 2025), and $4.3 million (Q1 2025).